-
DTC患者经手术、131I和TSH抑制治疗后大部分预后良好,然而,仍有部分DTC患者逐渐失去摄碘能力而进展成为碘难治性DTC(radioiodine-refractory DTC,RAIR-DTC)且预后不佳[1-2]。分子靶向药物在RAIR-DTC的治疗中具有重要作用,在我国,索拉非尼已被批准用于晚期DTC的治疗并被纳入相关指南[3]。分子靶向药物所致不良反应的防治是影响治疗成功与否的重要因素。笔者报道了1例目前在临床中极为少见的RAIR-DTC经索拉非尼治疗致亚急性肝衰竭的病例,其不良反应严重且持续时间较长,期望通过对该病例的临床资料进行分析以及对相关文献进行复习,加深对RAIR-DTC经索拉非尼治疗致亚急性肝衰竭这一不良反应的认识。
碘难治性分化型甲状腺癌经索拉非尼治疗致亚急性肝衰竭一例
A case of subacute liver failure caused by sorafenib treatment of radioiodine-refractory differentiated thyroid cancer
-
摘要: 笔者报道了1例碘难治性分化型甲状腺癌(RAIR-DTC)经索拉非尼治疗致亚急性肝衰竭的病例,并从临床症状、实验室检查、影像学检查、组织病理学检查结果以及患者的临床处置与转归等方面综合分析了该病的特点。笔者通过文献复习加深了对RAIR-DTC以及索拉非尼治疗晚期甲状腺癌的疗效和相关不良反应的认识,旨在提示临床医师在遇到相似病例时,不仅要关注索拉非尼的疗效,也要提高对应用靶向药物治疗RAIR-DTC所致不良反应的认知和管理,从而提高靶向治疗的疗效和安全性。Abstract: This paper reports a case of subacute liver failure caused by sorafenib treatment of radioiodine-refractory differentiated thyroid cancer (RAIR-DTC), and comprehensively analyzes the characteristics of the disease from clinical symptoms, laboratory examinations, imaging examinations, histopathological examination results as well as the patient's clinical treatment and outcome. Through literature review, the authors deepen the understanding of the characteristics of the disease, the efficacy and adverse reactions of sorafenib in the treatment of advanced thyroid cancer. This paper aims to remind clinicians that when encountering similar cases, they should not only pay attention to the efficacy of sorafenib treatment, but also improve the clinical awareness and management of adverse reactions related to the application of targeted drug therapy in RAIR-DTC, and ultimately improve the efficacy and safety of targeted therapy.
-
Key words:
-
-
[1] Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1−133. DOI: 10.1089/thy.2015.0020. [2] 丛慧, 梁军, 林岩松. 碘难治性分化型甲状腺癌的诊断与靶向治疗[J]. 国际放射医学核医学杂志, 2015, 39(1): 25−31. DOI: 10.3760/cma.j.issn.1673-4114.2015.01.007.
Cong H, Liang J, Lin YS. Diagnosis and targeted therapy of radioactive iodine-refractory differentiated thyroid cancer[J]. Int J Radiat Med Nucl Med, 2015, 39(1): 25−31. DOI: 10.3760/cma.j.issn.1673-4114.2015.01.007.[3] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2014版)[J]. 中华核医学与分子影像杂志, 2014, 34(4): 264−278. DOI: 10.3760/cma.j.issn.2095-2848.2014.04.002.
Nuclear Medicine Society of Chinese Medical Association. Guidelines for the treatment of differentiated thyroid cancer with 131I (2014 ed)[J]. Chin J Nucl Med Mol Imaging, 2014, 34(4): 264−278. DOI: 10.3760/cma.j.issn.2095-2848.2014.04.002.[4] Licitra L, Locati LD. Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for rethinking treatment strategies?[J]. Thyroid, 2014, 24(12): 1815. DOI: 10.1089/thy.2014.0288. [5] 中国临床肿瘤学会(CSCO)甲状腺癌专家委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医师协会外科医师分会甲状腺外科医师委员会, 等. 碘难治性分化型甲状腺癌的诊治管理共识(2019年版)[J]. 中国癌症杂志, 2019, 29(6): 476−480. DOI: 10.19401/j.cnki.1007-3639.2019.06.013.
Thyroid Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO), Thyroid Disease Professional Committee of the Chinese Society of Research Hospitals, Thyroid Surgeon Committee of the Surgeon Branch of the Chinese Medical Doctor Association, et al. Consensus on the diagnosis, treatment and management of radioiodine-refractory differentiated thyroid cancer (2019 ed)[J]. China Oncol, 2019, 29(6): 476−480. DOI: 10.19401/j.cnki.1007-3639.2019.06.013.[6] Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J]. Lancet Diabetes Endocrinol, 2014, 2(5): 356−358. DOI: 10.1016/S2213-8587(13)70215-8. [7] Lakshmanan A, Wojcicka A, Kotlarek M, et al. MicroRNA-339-5p modulates Na+/I− symporter-mediated radioiodide uptake[J]. Endocr Relat Cancer, 2015, 22(1): 11−21. DOI: 10.1530/ERC-14-0439. [8] Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319−328. DOI: 10.1016/S0140-6736(14)60421-9. [9] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7): 621−630. DOI: 10.1056/NEJMoa1406470. [10] 中国临床肿瘤学会(CSCO)甲状腺癌专家委员会. 碘难治性分化型甲状腺癌靶向药物不良反应管理专家共识(2018年版)[J]. 中国癌症杂志, 2018, 28(7): 545−553. DOI: 10.19401/j.cnki.1007-3639.2018.07.012.
Thyroid Cancer Expert Committee of the Chinese Society of Clinical Oncology (CSCO). Expert consensus on the management of adverse reactions of targeted drugs in radioactive iodine-refractory differentiated thyroid cancer (2018 ed)[J]. China Oncol, 2018, 28(7): 545−553. DOI: 10.19401/j.cnki.1007-3639.2018.07.012.